查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2096824

病毒載體市場－2026-2032年全球市場預測

Viral Vectors Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，病毒載體市場將成長至 114 億美元，複合年成長率為 14.96%。

主要市場統計數據
基準年 2025 42.9億美元
預計年份：2026年 49.2億美元
預測年份 2032 114億美元
複合年成長率 (%) 14.96%

病毒載體在現代細胞和基因治療、疫苗研發、腫瘤研究以及體內基因治療中發揮核心作用。這些基因遞送系統，包括腺結合病毒載體、慢病毒載體、逆轉錄病毒載體和單純皰疹病毒載體，用於將遺傳物質導入目標細胞，以達到治療和研究目的。基因治療臨床應用的不斷擴展、CAR-T療法和免疫療法研發管線的成長以及對先進生物製造技術的持續投資，都推動了對病毒載體的需求。監管機構正在發布日益詳細的關於載體表徵、療效測試、病毒複製測試、體內分佈、病毒脫落和長期隨訪的指導意見，強調了建立健全的品管系統的必要性。因此，病毒載體領域正從支持藥物研發轉向工業化、規範化和擴充性的生產模式，以支持轉化研究、臨床試驗和已通過核准的先進療法。

病毒載體研發與生產中的變革性變化

在病毒載體領域，正經歷從客製化小批量生產轉向標準化平台化生產的結構性轉變。腺相關病毒（AAV）載體因其組織親和性和相對良好的安全性，繼續廣泛應用於體內基因轉移；而慢病毒載體則因其在分裂和非分裂細胞中穩定的基因組整合能力，繼續在體外細胞治療中發揮關鍵作用。同時，腺病毒和其他載體系統繼續為疫苗平台、癌症免疫療法和基因編輯遞送研究提供支援。關鍵的轉型領域包括生產細胞株、懸浮培養系統、無血清培養基、改良的轉染技術、穩定的包裝系統以及密封自動化製程的開發。分析的複雜性也不斷增加，人們更加關注滿空衣殼比、載體基因組完整性、殘留宿主細胞DNA、外來性病原體檢測、效力以及製程變更後的可比性。監管審查、確保供應鏈韌性的優先事項以及在臨床和商業生產環境中提高可重複性的同時降低批次失敗風險的需求，正在加速這些變化。

人工智慧對病毒載體的累積影響

人工智慧正開始影響病毒載體的藥物發現、製程開發、品管和監管文件編制。機器學習模型可以透過分析序列-功能關係、免疫抗原性訊號、組織親和性和模式和生產限制來支持衣殼工程。在上游工程開發中，人工智慧驅動的實驗設計能夠最佳化轉染條件、細胞培養參數、培養基成分和收穫時間。在下游開發中，先進的分析技術可以改善層析法最佳化、雜質預測和產量一致性。人工智慧也被應用於GMP設施的各個環節，例如影像分析、數位化批次記錄、異常檢測和預測性維護。然而，其有效性取決於高品質的資料集、檢驗的模型、透明的管治以及對電腦系統和資料完整性相關監管要求的遵守。短期內，將人工智慧與高通量篩檢、製程分析技術和數位化品管相結合，有望在縮短開發週期的同時，加強病毒載體產品的證據構建，從而實現最大的價值。

病毒載體生態系的關鍵區域見解

亞太地區正透過不斷擴大的生物技術基礎設施、政府主導的生命科學計畫以及在中國、日本、韓國、印度、澳洲和新加坡等國活性化的臨床試驗活動，加強其在病毒載體研究和生產領域的作用。該地區受益大規模的患者群體、不斷擴展的學術轉化研究、再生醫學政策以及對符合GMP標準的細胞和基因治療設施的持續投資。在歐洲，先進療法的研發環境已相當成熟，這得益於跨境研究計畫、集中監管評估、以醫院為基礎的創新以及德國、法國、英國、義大利和西班牙等國的積極參與。歐洲先進治療藥物的法規結構支持對基因治療和基於病毒載體的產品進行系統評估，並持續強調品質、安全性、藥物安全監測和長期病患監測。北美仍然是病毒載體創新的活躍中心，這得益於成熟的生物技術生態系統、專業的契約製造、大學附屬醫療中心以及清晰的先進療法監管路徑。美國透過基因療法的核准、臨床開發和專業化生產，在很大程度上推動了該地區的發展勢頭，而加拿大則擁有強大的研究網路和細胞療法能力。在拉丁美洲，巴西和墨西哥正在逐步提升自身能力，推動生物醫學研究、臨床試驗參與、疫苗研發和監管現代化，但各國在獲取途徑、基礎設施和專業化生產能力方面仍存在差距。非洲是病毒載體應用的新興地區，在疫苗研究、感染疾病控制、基因組學能力和國際研究夥伴關係擁有許多機遇，但本地生產、人力資源開發和低溫運輸基礎設施建設仍然是關鍵的發展挑戰。在中東，精準醫療、基因組學和專業醫療基礎設施的投資正在穩步推進。特別是海灣國家，正在發展生物技術叢集、國家基因組學計畫和先進的臨床照護模式，這些都有助於未來獲得基於病毒載體的療法。

來自影響病毒載體引入的關鍵群體的見解

北約成員國與北美和歐洲的主要生物製藥市場高度重合，在這些市場中，供應鏈安全、生物安全、疫情防範和具有韌性的生產基礎設施與國家衛生戰略日益緊密地交織在一起。七國集團（G7）憑藉其成員國先進的監管機構、學術研究機構、GMP生產能力以及在細胞和基因療法的醫療技術評估和報銷方面已建立的討論機制，在病毒載體創新領域仍然具有影響力。金磚國家（BRICS）因其大規模的患者群體、國內對生物技術日益成長的熱情以及公共部門對醫療自主權的重視而具有重要的戰略意義。中國和印度在擴大生產能力和進行臨床研究方面尤其積極，而巴西、俄羅斯和南非則為疫苗和醫療保健取得提供了區域性的科學觀點和見解。歐盟透過其先進治療藥物（ATMP）框架、跨境研究資助、藥物安全監測系統和統一的品質標準，為病毒載體領域提供了結構最完善的監管和研究環境之一，儘管各成員國的具體實施情況可能有所不同。東協在病毒載體和先進療法的研發領域日益重要，其中新加坡在生物醫學製造和轉化研究方面主導，而馬來西亞、泰國、印尼、越南和菲律賓則正在拓展其臨床研究和生物製藥開發能力。海灣合作理事會（GCC）專注於基因組學、精準醫療和高優先級醫療保健領域的投資，旨在為獲得專科療法、開展臨床合作、推進罕見疾病計畫以及建立未來區域生物製造基礎設施創造機會。

主要國家病毒載體研究與生產的趨勢

中國正迅速擴大病毒載體生產、基因治療臨床活動和國內生物製藥創新，這得益於其對生命科學基礎設施的大量投資和大規模的臨床研究基地。美國是病毒載體開發的重要中心，擁有緊密的學術研究機構網路、臨床試驗設施、豐富的監管經驗和專業的生產設施。日本擁有完善的再生醫學和基因療法法規環境，並在產學合作方面具有優勢。同時，印度正在加強其在生技藥品、疫苗、合約開發和臨床研究方面的能力，並對罕見疾病和遺傳疾病的基因療法越來越感興趣。德國以其深厚的工程技術、生物製程專業知識和先進療法研究而聞名。英國在基因組學、病毒載體生產和臨床應用方面保持著強大的實力。澳洲支持早期臨床開發、轉化醫學和高品質的生物醫學研究基礎設施。法國透過其覆蓋全國的研究網路、公共研究機構和先進的臨床中心支持基因治療和疫苗創新。韓國正憑藉其在生技藥品生產、細胞療法研發和政府主導的生物技術舉措的優勢，建構具有競爭力的先進生物製造生態系統。義大利和西班牙繼續專注於以醫院為基礎的細胞和基因治療計畫、學術臨床研究以及提升先進療法的生產技術。加拿大在轉化科學、細胞療法研究和公私合營方面貢獻卓著，而俄羅斯儘管面臨地緣政治和供應鏈方面的阻礙，仍保持著其在病毒學、疫苗平台和生物醫學研究方面的科研實力。巴西是拉丁美洲最突出的生物技術市場，這得益於其公共衛生研究機構、疫苗專長以及對先進治療平台日益成長的興趣。墨西哥則在不斷擴大其臨床研究和生物製藥能力的同時，也對先進療法表現出越來越濃厚的興趣。

為病毒載體產業的領導者提供的實用建議

產業領導者應優先考慮能夠相容於多種載體類型並保持清晰的產品特定控制的平台製造策略。投資於可擴展的上游工程系統、閉迴路製程、自動化和經驗證的分析方法可以降低變異性並增強監管機構的信心。各組織應加強其在載體表徵、功效檢測開發、無菌保證、殘留雜質檢測、外來性微生物控制和可比性方案方面的能力，因為這些領域對臨床開發和生命週期管理至關重要。供應鏈韌性應包括關鍵原料的雙重來源、合格的質體DNA供應、穩健的低溫運輸物流以及針對一次性系統、特殊試劑和分析參考物質的緊急時應對計畫。領導者還應將數位化品質系統、電子批記錄和人工智慧驅動的製程監控與健全的資料管治、網路安全措施和驗證程序結合。與學術機構、醫院、監管機構和專業製造機構夥伴關係可以加速向臨床應用的過渡，但技術轉移計劃必須詳細、有據可查且基於風險。最後，為了減少研發過程中的不確定性，研發團隊應儘早與監管機構協商載體設計、體內分佈、消除、免疫抗原性、插入突變風險（如適用）以及長期追蹤要求等事宜。

深入了解病毒載體的調查方法

本執行摘要基於系統性的二手研究舉措，採用公開可查的資訊來源，包括監管指導文件、同行評審的科學文獻、臨床試驗註冊資訊、衛生機構公告、高級醫療政策出版刊物、專利和技術趨勢綜述，以及政府和機構的官方生物技術檢驗。研究途徑重點在於病毒載體科學、生產實踐、品管、區域生態系統成熟度和監管方向等方面的檢驗進展。資訊在多個可信任資訊來源類別中進行交叉引用，以減少對單一資訊來源解讀的依賴，並協調來自監管、科學和公共衛生資訊來源的既有證據和見解。本調查方法不涉及市場規模估算、市場佔有率、收入估算和預測；而是專注於對基因治療、細胞治療、疫苗和先進生技藥品領域相關人員的技術採納、區域能力、生產發展和戰略影響進行基於證據的定性評估。

關於病毒載體未來發展的結論

病毒載體仍然是下一代基因療法、先進細胞療法、癌症免疫療法和疫苗平台的基礎技術。可擴展的生產、改進的分析技術、日益成熟的監管體係以及人工智慧在藥物發現和製程最佳化中的選擇性應用正在改變這一領域的格局。儘管不同地區的生態系統在基礎設施、監管經驗、臨床能力和生產基礎設施方面存在差異，但隨著越來越多的國家投資於生物技術、基因組學、精準醫療和先進治療技術的能力建設，全球發展勢頭強勁。該領域的成功取決於可靠的載體設計、可重複的GMP生產、檢驗的品管、穩健的供應鏈以及早期的監管協調。將科學創新與營運規範結合的機構將更有利於推動安全、有效且可及的病毒載體療法的發展。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：病毒載體市場：依載體類型分類

  • 腺結合病毒
    • AAV2
    • AAV8
    • AAV9
  • 腺病毒
  • 慢病毒
  • 逆轉錄病毒

第8章：病毒載體市場：依治療領域分類

  • 心血管疾病
    • 冠狀動脈
    • 周邊血管
  • 感染疾病
    • 細菌
    • 病毒
  • 神經病變
    • 神經退化性疾病
    • 神經發育障礙
  • 腫瘤學
    • 血液疾病
    • 固體癌
  • 罕見疾病

第9章：病毒載體市場：依生產階段分類

  • 下游
    • 過濾
    • 配方
    • 純化
      • 層析法
      • 超速離心
  • 上游
    • 細胞增殖
    • 收成
    • 轉染

第10章：病毒載體市場：依應用分類

  • 細胞療法
    • CAR-T
    • 樹突狀細胞
    • TCR T
  • 基因治療
    • 體外
    • 體內
  • 研究
    • 基礎研究
    • 臨床前研究
  • 疫苗
    • 預防
    • 治療

第11章：病毒載體市場：依最終用戶分類

  • 生物製藥公司
  • 醫院和診所
  • 研究機構

第12章：病毒載體市場：按地區分類

  • 亞太地區
  • 歐洲
  • 北美洲
  • 拉丁美洲
  • 非洲
  • 中東

第13章：病毒載體市場：依組別分類

  • NATO
  • G7
  • BRICS
  • EU
  • ASEAN
  • GCC

第14章：病毒載體市場：依國家分類

  • 中國
  • 美國
  • 日本
  • 印度
  • 德國
  • 英國
  • 澳洲
  • 法國
  • 韓國
  • 義大利
  • 加拿大
  • 俄羅斯
  • 巴西
  • 墨西哥
  • 西班牙

第15章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • ABL Inc.
  • Batavia Biosciences BV by CJ Cheiljedang
  • Biovian Oy
  • Charles River Laboratories International, Inc.
  • Creative Biogene
  • Danaher Corporation
  • F. Hoffmann-La Roche Ltd.
  • FinVector Oy
  • FUJIFILM Holdings Corporation
  • GE HealthCare Technologies, Inc.
  • Genezen Laboratories, Inc.
  • Kaneka Eurogentec SA
  • Lonza Group Ltd.
  • Merck KGaA
  • Miltenyi Biotec GmbH
  • Novartis AG
  • Oxford Biomedica PLC
  • PackGene Biotech lnc.
  • Sanofi SA
  • Sirion-Biotech GmbH
  • Takara Bio Inc.
  • Thermo Fisher Scientific Inc.
  • uniQure NV
  • VGXI, Inc. by GeneOne Life Science
  • Waisman Biomanufacturing
  • Wuxi AppTec Co., Ltd.
Product Code: MRR-957C47F9405B

The Viral Vectors Market is projected to grow by USD 11.40 billion at a CAGR of 14.96% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 4.29 billion
Estimated Year [2026] USD 4.92 billion
Forecast Year [2032] USD 11.40 billion
CAGR (%) 14.96%

Viral vectors are central to modern cell and gene therapy, vaccine development, oncology research, and in vivo genetic medicine. These engineered delivery systems, including adeno-associated virus vectors, lentiviral vectors, adenoviral vectors, retroviral vectors, and herpes simplex virus vectors, are used to transfer genetic material into target cells for therapeutic or research purposes. Demand is being shaped by the growing clinical use of gene therapies, expanding CAR-T and immune-cell therapy pipelines, and continued investment in advanced biomanufacturing. Regulatory agencies have issued increasingly detailed guidance on vector characterization, potency assays, replication-competent virus testing, biodistribution, shedding, and long-term follow-up, reinforcing the need for robust quality systems. The viral vectors landscape is therefore moving beyond discovery-stage enablement toward industrialized, compliant, and scalable manufacturing models that support translational research, clinical trials, and approved advanced therapies.

Transformative Shifts in Viral Vector Development and Manufacturing

The viral vectors sector is undergoing a structural shift from bespoke, small-batch production toward standardized, platform-based manufacturing. AAV vectors remain widely used for in vivo gene delivery because of their tissue tropism and relatively favorable safety profile, while lentiviral vectors continue to be important for ex vivo cell therapies due to stable genomic integration in dividing and non-dividing cells. At the same time, adenoviral and other vector systems continue to support vaccine platforms, cancer immunotherapy, and gene-editing delivery research. Key transformation areas include producer cell line development, suspension-based culture systems, serum-free media, improved transfection technologies, stable packaging systems, and closed, automated processing. Analytical complexity is also rising, with greater attention to full-to-empty capsid ratios, vector genome integrity, residual host cell DNA, adventitious agent testing, potency, and comparability after process changes. These shifts are being accelerated by regulatory scrutiny, supply-chain resilience priorities, and the need to reduce batch failure risk while improving reproducibility across clinical and commercial production environments.

Cumulative Impact of Artificial Intelligence on Viral Vectors

Artificial intelligence is beginning to influence viral vector discovery, process development, quality control, and regulatory documentation. Machine learning models can support capsid engineering by analyzing sequence-function relationships, immunogenicity signals, tissue tropism patterns, and manufacturability constraints. In upstream development, AI-enabled design of experiments can help optimize transfection conditions, cell culture parameters, media composition, and harvest timing. In downstream processing, advanced analytics can improve chromatography optimization, impurity prediction, and yield consistency. AI is also being applied to image analysis, digital batch records, anomaly detection, and predictive maintenance across GMP facilities. However, its impact depends on high-quality datasets, validated models, transparent governance, and alignment with regulatory expectations for computerized systems and data integrity. The strongest near-term value is likely to come from combining AI with high-throughput screening, process analytical technology, and digital quality management to shorten development cycles while strengthening evidence generation for viral vector products.

Key Regional Insights Across the Viral Vectors Ecosystem

Asia-Pacific is strengthening its role in viral vector research and manufacturing through expanding biotechnology infrastructure, government-backed life sciences programs, and rising clinical trial activity in China, Japan, South Korea, India, Australia, and Singapore. The region benefits from large patient populations, growing academic translational research, regenerative medicine policies, and increasing investment in GMP-compliant cell and gene therapy facilities. Europe has a deeply established advanced therapy environment, supported by cross-border research programs, centralized regulatory assessment, hospital-based innovation, and strong activity in Germany, France, the United Kingdom, Italy, and Spain. The European regulatory framework for advanced therapy medicinal products supports structured evaluation of gene therapies and viral vector-enabled products, with sustained emphasis on quality, safety, pharmacovigilance, and long-term patient monitoring. North America remains a highly active hub for viral vector innovation, supported by a mature biotechnology ecosystem, specialized contract manufacturing capacity, academic medical centers, and defined regulatory pathways for advanced therapies. The United States drives much of the region's momentum through gene therapy approvals, clinical development, and manufacturing specialization, while Canada contributes strong research networks and cell therapy capabilities. Latin America is gradually building capacity, with Brazil and Mexico advancing biomedical research, clinical trial participation, vaccine capabilities, and regulatory modernization, although access, infrastructure, and specialized manufacturing remain uneven. Africa remains an emerging geography for viral vector applications, with opportunities linked to vaccine research, infectious disease preparedness, genomics capacity, and international research partnerships, though local manufacturing, workforce development, and cold-chain infrastructure remain key development priorities. The Middle East is investing in precision medicine, genomics, and specialized healthcare infrastructure, particularly in Gulf states that are developing biotechnology clusters, national genome programs, and advanced clinical care models that may support future viral vector-enabled therapy access.

Key Group Insights Shaping Viral Vector Adoption

NATO member countries overlap significantly with leading biopharmaceutical markets in North America and Europe, where supply-chain security, biosecurity, pandemic preparedness, and resilient manufacturing infrastructure are increasingly linked to national health strategy. The G7 remains influential in viral vector innovation because its members host advanced regulatory agencies, academic research institutions, GMP manufacturing capacity, and established health technology assessment and reimbursement discussions for cell and gene therapies. BRICS countries are strategically important because they combine large patient populations, growing domestic biotechnology ambitions, and public-sector interest in healthcare sovereignty; China and India are particularly active in manufacturing expansion and clinical research, while Brazil, Russia, and South Africa contribute regional scientific, vaccine, and healthcare access perspectives. The European Union provides one of the most structured regulatory and research environments for viral vectors through advanced therapy medicinal product frameworks, cross-country research funding, pharmacovigilance systems, and harmonized quality expectations, although implementation can vary by member state. ASEAN is becoming increasingly relevant to viral vector and advanced therapy development as Singapore leads in biomedical manufacturing and translational research, while Malaysia, Thailand, Indonesia, Vietnam, and the Philippines expand clinical research capacity and biopharmaceutical capabilities. The GCC is emphasizing genomics, precision medicine, and high-acuity healthcare investment, creating opportunities for specialized therapy access, clinical collaborations, rare disease programs, and future regional biomanufacturing foundations.

Key Country Insights in Viral Vector Research and Manufacturing

China is rapidly expanding viral vector manufacturing, gene therapy clinical activity, and domestic biopharmaceutical innovation, supported by substantial investment in life sciences infrastructure and a large clinical research base. The United States is a leading center for viral vector development, supported by a dense network of academic research institutions, clinical trial sites, regulatory experience, and specialized manufacturing facilities. Japan has a well-established regenerative medicine and gene therapy regulatory environment and strong academic-industry collaboration, while India is developing capabilities in biologics, vaccines, contract development, and clinical research, with increasing interest in gene therapy for rare and inherited diseases. Germany is notable for engineering depth, bioprocessing expertise, and advanced therapy research, while the United Kingdom maintains strong capabilities in genomics, viral vector manufacturing, and clinical translation. Australia supports early-phase clinical development, translational medicine, and high-quality biomedical research infrastructure. France supports gene therapy and vaccine innovation through national research networks, public research institutions, and advanced clinical centers. South Korea is building a competitive advanced biomanufacturing ecosystem, with strengths in biologics production, cell therapy development, and government-backed biotechnology initiatives. Italy and Spain continue to advance hospital-based cell and gene therapy programs, academic clinical research, and advanced therapy manufacturing know-how. Canada contributes strong translational science, cell therapy research, and public-private collaboration, while Russia maintains scientific capabilities in virology, vaccine platforms, and biomedical research despite geopolitical and supply-chain constraints. Brazil is Latin America's most prominent biotechnology market, with public health research institutions, vaccine expertise, and increasing attention to advanced therapeutic platforms, and Mexico is expanding clinical research and biopharmaceutical capabilities with growing interest in advanced therapies.

Actionable Recommendations for Viral Vector Industry Leaders

Industry leaders should prioritize platform manufacturing strategies that can support multiple vector types while maintaining clear product-specific controls. Investments in scalable upstream systems, closed processing, automation, and validated analytical methods can reduce variability and support regulatory confidence. Organizations should strengthen capabilities in vector characterization, potency assay development, sterility assurance, residual impurity testing, adventitious agent control, and comparability protocols, as these areas are critical for clinical progression and lifecycle management. Supply-chain resilience should include dual sourcing of critical raw materials, qualified plasmid DNA supply, robust cold-chain logistics, and contingency planning for single-use systems, specialized reagents, and analytical reference standards. Leaders should also integrate digital quality systems, electronic batch records, and AI-assisted process monitoring with strong data governance, cybersecurity controls, and validation procedures. Partnerships with academic centers, hospitals, regulators, and specialized manufacturing organizations can accelerate translation, but technology transfer plans must be detailed, documented, and risk-based. Finally, teams should engage early with regulators on vector design, biodistribution, shedding, immunogenicity, insertional mutagenesis risk where relevant, and long-term follow-up requirements to reduce development uncertainty.

Research Methodology for Viral Vector Insights

This executive summary is developed through a structured secondary research approach using publicly available and verifiable sources, including regulatory guidance documents, peer-reviewed scientific literature, clinical trial registries, health agency communications, advanced therapy policy publications, patent and technology trend reviews, and official government or institutional biotechnology initiatives. The analysis emphasizes validated developments in viral vector science, manufacturing practices, quality control, regional ecosystem maturity, and regulatory direction. Information is cross-checked across multiple credible source categories to reduce dependence on single-source interpretation and to align insights with established evidence from regulatory, scientific, and public health sources. The methodology excludes market sizing, market share, revenue estimation, and forecasting, focusing instead on evidence-based qualitative assessment of technology adoption, regional capabilities, manufacturing evolution, and strategic implications for stakeholders in gene therapy, cell therapy, vaccines, and advanced biologics.

Conclusion on the Future of Viral Vectors

Viral vectors remain a foundational technology for the next generation of genetic medicines, advanced cell therapies, cancer immunotherapies, and vaccine platforms. The landscape is being reshaped by scalable manufacturing, improved analytics, regulatory maturity, and the selective use of artificial intelligence in discovery and process optimization. Regional ecosystems differ in infrastructure, regulatory experience, clinical capacity, and manufacturing readiness, but global momentum is clear as more countries invest in biotechnology, genomics, precision medicine, and advanced therapy capabilities. Success in this field will depend on reliable vector design, reproducible GMP production, validated quality controls, resilient supply chains, and early regulatory alignment. Organizations that combine scientific innovation with operational discipline will be best positioned to advance safe, effective, and accessible viral vector-enabled therapies.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Viral Vectors Market, by Vector Type

  • 7.1. Introduction
  • 7.2. Adeno Associated Virus
    • 7.2.1. AAV2
    • 7.2.2. AAV8
    • 7.2.3. AAV9
  • 7.3. Adenovirus
  • 7.4. Lentivirus
  • 7.5. Retrovirus

8. Viral Vectors Market, by Therapeutic Area

  • 8.1. Introduction
  • 8.2. Cardiovascular Disorders
    • 8.2.1. Coronary
    • 8.2.2. Peripheral Vascular
  • 8.3. Infectious Disease
    • 8.3.1. Bacterial
    • 8.3.2. Viral
  • 8.4. Neurological Disorders
    • 8.4.1. Neurodegenerative
    • 8.4.2. Neurodevelopmental
  • 8.5. Oncology
    • 8.5.1. Hematological
    • 8.5.2. Solid Tumor
  • 8.6. Rare Diseases

9. Viral Vectors Market, by Production Stage

  • 9.1. Introduction
  • 9.2. Downstream
    • 9.2.1. Filtration
    • 9.2.2. Formulation
    • 9.2.3. Purification
      • 9.2.3.1. Chromatography
      • 9.2.3.2. Ultracentrifugation
  • 9.3. Upstream
    • 9.3.1. Cell Expansion
    • 9.3.2. Harvesting
    • 9.3.3. Transfection

10. Viral Vectors Market, by Application

  • 10.1. Introduction
  • 10.2. Cell Therapy
    • 10.2.1. Car T
    • 10.2.2. Dendritic
    • 10.2.3. TCR T
  • 10.3. Gene Therapy
    • 10.3.1. Ex Vivo
    • 10.3.2. In Vivo
  • 10.4. Research
    • 10.4.1. Basic Research
    • 10.4.2. Preclinical Research
  • 10.5. Vaccine
    • 10.5.1. Prophylactic
    • 10.5.2. Therapeutic

11. Viral Vectors Market, by End User

  • 11.1. Introduction
  • 11.2. Biopharma Companies
  • 11.3. Hospitals And Clinics
  • 11.4. Research Institutes

12. Viral Vectors Market, by Region

  • 12.1. Asia-Pacific
  • 12.2. Europe
  • 12.3. North America
  • 12.4. Latin America
  • 12.5. Africa
  • 12.6. Middle East

13. Viral Vectors Market, by Group

  • 13.1. NATO
  • 13.2. G7
  • 13.3. BRICS
  • 13.4. European Union
  • 13.5. ASEAN
  • 13.6. GCC

14. Viral Vectors Market, by Country

  • 14.1. China
  • 14.2. United States
  • 14.3. Japan
  • 14.4. India
  • 14.5. Germany
  • 14.6. United Kingdom
  • 14.7. Australia
  • 14.8. France
  • 14.9. South Korea
  • 14.10. Italy
  • 14.11. Canada
  • 14.12. Russia
  • 14.13. Brazil
  • 14.14. Mexico
  • 14.15. Spain

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2025
  • 15.2. FPNV Positioning Matrix, 2025
  • 15.3. Market Concentration Analysis, 2025
    • 15.3.1. Concentration Ratio (CR)
    • 15.3.2. Herfindahl Hirschman Index (HHI)
  • 15.4. Recent Developments & Impact Analysis, 2025
  • 15.5. Product Portfolio Analysis, 2025
  • 15.6. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. ABL Inc.
  • 16.2. Batavia Biosciences B.V. by CJ Cheiljedang
  • 16.3. Biovian Oy
  • 16.4. Charles River Laboratories International, Inc.
  • 16.5. Creative Biogene
  • 16.6. Danaher Corporation
  • 16.7. F. Hoffmann-La Roche Ltd.
  • 16.8. FinVector Oy
  • 16.9. FUJIFILM Holdings Corporation
  • 16.10. GE HealthCare Technologies, Inc.
  • 16.11. Genezen Laboratories, Inc.
  • 16.12. Kaneka Eurogentec S.A.
  • 16.13. Lonza Group Ltd.
  • 16.14. Merck KGaA
  • 16.15. Miltenyi Biotec GmbH
  • 16.16. Novartis AG
  • 16.17. Oxford Biomedica PLC
  • 16.18. PackGene Biotech lnc.
  • 16.19. Sanofi SA
  • 16.20. Sirion-Biotech GmbH
  • 16.21. Takara Bio Inc.
  • 16.22. Thermo Fisher Scientific Inc.
  • 16.23. uniQure N.V.
  • 16.24. VGXI, Inc. by GeneOne Life Science
  • 16.25. Waisman Biomanufacturing
  • 16.26. Wuxi AppTec Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL VIRAL VECTORS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL VIRAL VECTORS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL VIRAL VECTORS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL VIRAL VECTORS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL VIRAL VECTORS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL VIRAL VECTORS MARKET SIZE, BY VECTOR TYPE, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL VIRAL VECTORS MARKET SIZE, BY VECTOR TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL VIRAL VECTORS MARKET SIZE, BY PRODUCTION STAGE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL VIRAL VECTORS MARKET SIZE, BY PRODUCTION STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL VIRAL VECTORS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL VIRAL VECTORS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL VIRAL VECTORS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL VIRAL VECTORS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL VIRAL VECTORS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL VIRAL VECTORS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL VIRAL VECTORS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 23. GLOBAL VIRAL VECTORS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL VIRAL VECTORS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL VIRAL VECTORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL VIRAL VECTORS MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ADENO ASSOCIATED VIRUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ADENO ASSOCIATED VIRUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ADENO ASSOCIATED VIRUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL AAV2 MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL AAV2 MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL AAV2 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL AAV8 MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL AAV8 MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL AAV8 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL AAV9 MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL AAV9 MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL AAV9 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ADENOVIRUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ADENOVIRUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ADENOVIRUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL LENTIVIRUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL LENTIVIRUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL LENTIVIRUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL RETROVIRUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL RETROVIRUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL RETROVIRUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CARDIOVASCULAR DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CARDIOVASCULAR DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CARDIOVASCULAR DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CORONARY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CORONARY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CORONARY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PERIPHERAL VASCULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PERIPHERAL VASCULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PERIPHERAL VASCULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL INFECTIOUS DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL INFECTIOUS DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL INFECTIOUS DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BACTERIAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BACTERIAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BACTERIAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL VIRAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL VIRAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL VIRAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL NEUROLOGICAL DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL NEUROLOGICAL DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL NEUROLOGICAL DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL NEURODEGENERATIVE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL NEURODEGENERATIVE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL NEURODEGENERATIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL NEURODEVELOPMENTAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL NEURODEVELOPMENTAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL NEURODEVELOPMENTAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL HEMATOLOGICAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL HEMATOLOGICAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL HEMATOLOGICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL SOLID TUMOR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL SOLID TUMOR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL SOLID TUMOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL RARE DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL RARE DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL RARE DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL VIRAL VECTORS MARKET SIZE, BY PRODUCTION STAGE, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL DOWNSTREAM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL DOWNSTREAM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL DOWNSTREAM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL FILTRATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL FILTRATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL FILTRATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL FORMULATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL FORMULATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL FORMULATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL PURIFICATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL PURIFICATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL PURIFICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CHROMATOGRAPHY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CHROMATOGRAPHY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CHROMATOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ULTRACENTRIFUGATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ULTRACENTRIFUGATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ULTRACENTRIFUGATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL UPSTREAM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL UPSTREAM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL UPSTREAM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL CELL EXPANSION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CELL EXPANSION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL CELL EXPANSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL HARVESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL HARVESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL HARVESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL TRANSFECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL TRANSFECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL TRANSFECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL CELL THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL CELL THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL CAR T MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL CAR T MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL CAR T MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL DENDRITIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL DENDRITIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL DENDRITIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL TCR T MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL TCR T MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL TCR T MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL GENE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL GENE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL EX VIVO MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL EX VIVO MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL EX VIVO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL IN VIVO MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL IN VIVO MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL IN VIVO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL RESEARCH MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL RESEARCH MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL RESEARCH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL BASIC RESEARCH MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL BASIC RESEARCH MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL BASIC RESEARCH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL PRECLINICAL RESEARCH MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL PRECLINICAL RESEARCH MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL PRECLINICAL RESEARCH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL PROPHYLACTIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL PROPHYLACTIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL PROPHYLACTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL THERAPEUTIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL THERAPEUTIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL BIOPHARMA COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL BIOPHARMA COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL BIOPHARMA COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL HOSPITALS AND CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL HOSPITALS AND CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL HOSPITALS AND CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL VIRAL VECTORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC VIRAL VECTORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC VIRAL VECTORS MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC VIRAL VECTORS MARKET SIZE, BY ADENO ASSOCIATED VIRUS, 2018-2032 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC VIRAL VECTORS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC VIRAL VECTORS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC VIRAL VECTORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC VIRAL VECTORS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC VIRAL VECTORS MARKET SIZE, BY PRODUCTION STAGE, 2018-2032 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC VIRAL VECTORS MARKET SIZE, BY DOWNSTREAM, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC VIRAL VECTORS MARKET SIZE, BY PURIFICATION, 2018-2032 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC VIRAL VECTORS MARKET SIZE, BY UPSTREAM, 2018-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC VIRAL VECTORS MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC VIRAL VECTORS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC VIRAL VECTORS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC VIRAL VECTORS MARKET SIZE, BY VACCINE, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE VIRAL VECTORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE VIRAL VECTORS MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE VIRAL VECTORS MARKET SIZE, BY ADENO ASSOCIATED VIRUS, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE VIRAL VECTORS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE VIRAL VECTORS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE VIRAL VECTORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE VIRAL VECTORS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE VIRAL VECTORS MARKET SIZE, BY PRODUCTION STAGE, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE VIRAL VECTORS MARKET SIZE, BY DOWNSTREAM, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE VIRAL VECTORS MARKET SIZE, BY PURIFICATION, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE VIRAL VECTORS MARKET SIZE, BY UPSTREAM, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE VIRAL VECTORS MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE VIRAL VECTORS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE VIRAL VECTORS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE VIRAL VECTORS MARKET SIZE, BY VACCINE, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA VIRAL VECTORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 184. NORTH AMERICA VIRAL VECTORS MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA VIRAL VECTORS MARKET SIZE, BY ADENO ASSOCIATED VIRUS, 2018-2032 (USD MILLION)
  • TABLE 186. NORTH AMERICA VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA VIRAL VECTORS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 188. NORTH AMERICA VIRAL VECTORS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA VIRAL VECTORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 190. NORTH AMERICA VIRAL VECTORS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA VIRAL VECTORS MARKET SIZE, BY PRODUCTION STAGE, 2018-2032 (USD MILLION)
  • TABLE 192. NORTH AMERICA VIRAL VECTORS MARKET SIZE, BY DOWNSTREAM, 2018-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA VIRAL VECTORS MARKET SIZE, BY PURIFICATION, 2018-2032 (USD MILLION)
  • TABLE 194. NORTH AMERICA VIRAL VECTORS MARKET SIZE, BY UPSTREAM, 2018-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 196. NORTH AMERICA VIRAL VECTORS MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 197. NORTH AMERICA VIRAL VECTORS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 198. NORTH AMERICA VIRAL VECTORS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA VIRAL VECTORS MARKET SIZE, BY VACCINE, 2018-2032 (USD MILLION)
  • TABLE 200. NORTH AMERICA VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA VIRAL VECTORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 202. LATIN AMERICA VIRAL VECTORS MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA VIRAL VECTORS MARKET SIZE, BY ADENO ASSOCIATED VIRUS, 2018-2032 (USD MILLION)
  • TABLE 204. LATIN AMERICA VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA VIRAL VECTORS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 206. LATIN AMERICA VIRAL VECTORS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA VIRAL VECTORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 208. LATIN AMERICA VIRAL VECTORS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA VIRAL VECTORS MARKET SIZE, BY PRODUCTION STAGE, 2018-2032 (USD MILLION)
  • TABLE 210. LATIN AMERICA VIRAL VECTORS MARKET SIZE, BY DOWNSTREAM, 2018-2032 (USD MILLION)
  • TABLE 211. LATIN AMERICA VIRAL VECTORS MARKET SIZE, BY PURIFICATION, 2018-2032 (USD MILLION)
  • TABLE 212. LATIN AMERICA VIRAL VECTORS MARKET SIZE, BY UPSTREAM, 2018-2032 (USD MILLION)
  • TABLE 213. LATIN AMERICA VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 214. LATIN AMERICA VIRAL VECTORS MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA VIRAL VECTORS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 216. LATIN AMERICA VIRAL VECTORS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA VIRAL VECTORS MARKET SIZE, BY VACCINE, 2018-2032 (USD MILLION)
  • TABLE 218. LATIN AMERICA VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 219. AFRICA VIRAL VECTORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 220. AFRICA VIRAL VECTORS MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. AFRICA VIRAL VECTORS MARKET SIZE, BY ADENO ASSOCIATED VIRUS, 2018-2032 (USD MILLION)
  • TABLE 222. AFRICA VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 223. AFRICA VIRAL VECTORS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 224. AFRICA VIRAL VECTORS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 225. AFRICA VIRAL VECTORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 226. AFRICA VIRAL VECTORS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 227. AFRICA VIRAL VECTORS MARKET SIZE, BY PRODUCTION STAGE, 2018-2032 (USD MILLION)
  • TABLE 228. AFRICA VIRAL VECTORS MARKET SIZE, BY DOWNSTREAM, 2018-2032 (USD MILLION)
  • TABLE 229. AFRICA VIRAL VECTORS MARKET SIZE, BY PURIFICATION, 2018-2032 (USD MILLION)
  • TABLE 230. AFRICA VIRAL VECTORS MARKET SIZE, BY UPSTREAM, 2018-2032 (USD MILLION)
  • TABLE 231. AFRICA VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 232. AFRICA VIRAL VECTORS MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 233. AFRICA VIRAL VECTORS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 234. AFRICA VIRAL VECTORS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 235. AFRICA VIRAL VECTORS MARKET SIZE, BY VACCINE, 2018-2032 (USD MILLION)
  • TABLE 236. AFRICA VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 237. MIDDLE EAST VIRAL VECTORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 238. MIDDLE EAST VIRAL VECTORS MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST VIRAL VECTORS MARKET SIZE, BY ADENO ASSOCIATED VIRUS, 2018-2032 (USD MILLION)
  • TABLE 240. MIDDLE EAST VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 241. MIDDLE EAST VIRAL VECTORS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 242. MIDDLE EAST VIRAL VECTORS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 243. MIDDLE EAST VIRAL VECTORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 244. MIDDLE EAST VIRAL VECTORS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 245. MIDDLE EAST VIRAL VECTORS MARKET SIZE, BY PRODUCTION STAGE, 2018-2032 (USD MILLION)
  • TABLE 246. MIDDLE EAST VIRAL VECTORS MARKET SIZE, BY DOWNSTREAM, 2018-2032 (USD MILLION)
  • TABLE 247. MIDDLE EAST VIRAL VECTORS MARKET SIZE, BY PURIFICATION, 2018-2032 (USD MILLION)
  • TABLE 248. MIDDLE EAST VIRAL VECTORS MARKET SIZE, BY UPSTREAM, 2018-2032 (USD MILLION)
  • TABLE 249. MIDDLE EAST VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 250. MIDDLE EAST VIRAL VECTORS MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 251. MIDDLE EAST VIRAL VECTORS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 252. MIDDLE EAST VIRAL VECTORS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 253. MIDDLE EAST VIRAL VECTORS MARKET SIZE, BY VACCINE, 2018-2032 (USD MILLION)
  • TABLE 254. MIDDLE EAST VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 255. GLOBAL VIRAL VECTORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 256. NATO VIRAL VECTORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 257. NATO VIRAL VECTORS MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 258. NATO VIRAL VECTORS MARKET SIZE, BY ADENO ASSOCIATED VIRUS, 2018-2032 (USD MILLION)
  • TABLE 259. NATO VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 260. NATO VIRAL VECTORS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 261. NATO VIRAL VECTORS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 262. NATO VIRAL VECTORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 263. NATO VIRAL VECTORS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 264. NATO VIRAL VECTORS MARKET SIZE, BY PRODUCTION STAGE, 2018-2032 (USD MILLION)
  • TABLE 265. NATO VIRAL VECTORS MARKET SIZE, BY DOWNSTREAM, 2018-2032 (USD MILLION)
  • TABLE 266. NATO VIRAL VECTORS MARKET SIZE, BY PURIFICATION, 2018-2032 (USD MILLION)
  • TABLE 267. NATO VIRAL VECTORS MARKET SIZE, BY UPSTREAM, 2018-2032 (USD MILLION)
  • TABLE 268. NATO VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 269. NATO VIRAL VECTORS MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 270. NATO VIRAL VECTORS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 271. NATO VIRAL VECTORS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 272. NATO VIRAL VECTORS MARKET SIZE, BY VACCINE, 2018-2032 (USD MILLION)
  • TABLE 273. NATO VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 274. G7 VIRAL VECTORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 275. G7 VIRAL VECTORS MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 276. G7 VIRAL VECTORS MARKET SIZE, BY ADENO ASSOCIATED VIRUS, 2018-2032 (USD MILLION)
  • TABLE 277. G7 VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 278. G7 VIRAL VECTORS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 279. G7 VIRAL VECTORS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 280. G7 VIRAL VECTORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 281. G7 VIRAL VECTORS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 282. G7 VIRAL VECTORS MARKET SIZE, BY PRODUCTION STAGE, 2018-2032 (USD MILLION)
  • TABLE 283. G7 VIRAL VECTORS MARKET SIZE, BY DOWNSTREAM, 2018-2032 (USD MILLION)
  • TABLE 284. G7 VIRAL VECTORS MARKET SIZE, BY PURIFICATION, 2018-2032 (USD MILLION)
  • TABLE 285. G7 VIRAL VECTORS MARKET SIZE, BY UPSTREAM, 2018-2032 (USD MILLION)
  • TABLE 286. G7 VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 287. G7 VIRAL VECTORS MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 288. G7 VIRAL VECTORS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 289. G7 VIRAL VECTORS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 290. G7 VIRAL VECTORS MARKET SIZE, BY VACCINE, 2018-2032 (USD MILLION)
  • TABLE 291. G7 VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 292. BRICS VIRAL VECTORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 293. BRICS VIRAL VECTORS MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 294. BRICS VIRAL VECTORS MARKET SIZE, BY ADENO ASSOCIATED VIRUS, 2018-2032 (USD MILLION)
  • TABLE 295. BRICS VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 296. BRICS VIRAL VECTORS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 297. BRICS VIRAL VECTORS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 298. BRICS VIRAL VECTORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 299. BRICS VIRAL VECTORS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 300. BRICS VIRAL VECTORS MARKET SIZE, BY PRODUCTION STAGE, 2018-2032 (USD MILLION)
  • TABLE 301. BRICS VIRAL VECTORS MARKET SIZE, BY DOWNSTREAM, 2018-2032 (USD MILLION)
  • TABLE 302. BRICS VIRAL VECTORS MARKET SIZE, BY PURIFICATION, 2018-2032 (USD MILLION)
  • TABLE 303. BRICS VIRAL VECTORS MARKET SIZE, BY UPSTREAM, 2018-2032 (USD MILLION)
  • TABLE 304. BRICS VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 305. BRICS VIRAL VECTORS MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 306. BRICS VIRAL VECTORS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 307. BRICS VIRAL VECTORS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 308. BRICS VIRAL VECTORS MARKET SIZE, BY VACCINE, 2018-2032 (USD MILLION)
  • TABLE 309. BRICS VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 310. EUROPEAN UNION VIRAL VECTORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 311. EUROPEAN UNION VIRAL VECTORS MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 312. EUROPEAN UNION VIRAL VECTORS MARKET SIZE, BY ADENO ASSOCIATED VIRUS, 2018-2032 (USD MILLION)
  • TABLE 313. EUROPEAN UNION VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 314. EUROPEAN UNION VIRAL VECTORS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 315. EUROPEAN UNION VIRAL VECTORS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 316. EUROPEAN UNION VIRAL VECTORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 317. EUROPEAN UNION VIRAL VECTORS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 318. EUROPEAN UNION VIRAL VECTORS MARKET SIZE, BY PRODUCTION STAGE, 2018-2032 (USD MILLION)
  • TABLE 319. EUROPEAN UNION VIRAL VECTORS MARKET SIZE, BY DOWNSTREAM, 2018-2032 (USD MILLION)
  • TABLE 320. EUROPEAN UNION VIRAL VECTORS MARKET SIZE, BY PURIFICATION, 2018-2032 (USD MILLION)
  • TABLE 321. EUROPEAN UNION VIRAL VECTORS MARKET SIZE, BY UPSTREAM, 2018-2032 (USD MILLION)
  • TABLE 322. EUROPEAN UNION VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 323. EUROPEAN UNION VIRAL VECTORS MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 324. EUROPEAN UNION VIRAL VECTORS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 325. EUROPEAN UNION VIRAL VECTORS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 326. EUROPEAN UNION VIRAL VECTORS MARKET SIZE, BY VACCINE, 2018-2032 (USD MILLION)
  • TABLE 327. EUROPEAN UNION VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 328. ASEAN VIRAL VECTORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 329. ASEAN VIRAL VECTORS MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 330. ASEAN VIRAL VECTORS MARKET SIZE, BY ADENO ASSOCIATED VIRUS, 2018-2032 (USD MILLION)
  • TABLE 331. ASEAN VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 332. ASEAN VIRAL VECTORS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 333. ASEAN VIRAL VECTORS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 334. ASEAN VIRAL VECTORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 335. ASEAN VIRAL VECTORS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 336. ASEAN VIRAL VECTORS MARKET SIZE, BY PRODUCTION STAGE, 2018-2032 (USD MILLION)
  • TABLE 337. ASEAN VIRAL VECTORS MARKET SIZE, BY DOWNSTREAM, 2018-2032 (USD MILLION)
  • TABLE 338. ASEAN VIRAL VECTORS MARKET SIZE, BY PURIFICATION, 2018-2032 (USD MILLION)
  • TABLE 339. ASEAN VIRAL VECTORS MARKET SIZE, BY UPSTREAM, 2018-2032 (USD MILLION)
  • TABLE 340. ASEAN VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 341. ASEAN VIRAL VECTORS MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 342. ASEAN VIRAL VECTORS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 343. ASEAN VIRAL VECTORS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 344. ASEAN VIRAL VECTORS MARKET SIZE, BY VACCINE, 2018-2032 (USD MILLION)
  • TABLE 345. ASEAN VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 346. GCC VIRAL VECTORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 347. GCC VIRAL VECTORS MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 348. GCC VIRAL VECTORS MARKET SIZE, BY ADENO ASSOCIATED VIRUS, 2018-2032 (USD MILLION)
  • TABLE 349. GCC VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 350. GCC VIRAL VECTORS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 351. GCC VIRAL VECTORS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 352. GCC VIRAL VECTORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 353. GCC VIRAL VECTORS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 354. GCC VIRAL VECTORS MARKET SIZE, BY PRODUCTION STAGE, 2018-2032 (USD MILLION)
  • TABLE 355. GCC VIRAL VECTORS MARKET SIZE, BY DOWNSTREAM, 2018-2032 (USD MILLION)
  • TABLE 356. GCC VIRAL VECTORS MARKET SIZE, BY PURIFICATION, 2018-2032 (USD MILLION)
  • TABLE 357. GCC VIRAL VECTORS MARKET SIZE, BY UPSTREAM, 2018-2032 (USD MILLION)
  • TABLE 358. GCC VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 359. GCC VIRAL VECTORS MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 360. GCC VIRAL VECTORS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 361. GCC VIRAL VECTORS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 362. GCC VIRAL VECTORS MARKET SIZE, BY VACCINE, 2018-2032 (USD MILLION)
  • TABLE 363. GCC VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 364. GLOBAL VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 365. CHINA VIRAL VECTORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 366. CHINA VIRAL VECTORS MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 367. CHINA VIRAL VECTORS MARKET SIZE, BY ADENO ASSOCIATED VIRUS, 2018-2032 (USD MILLION)
  • TABLE 368. CHINA VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 369. CHINA VIRAL VECTORS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 370. CHINA VIRAL VECTORS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 371. CHINA VIRAL VECTORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 372. CHINA VIRAL VECTORS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 373. CHINA VIRAL VECTORS MARKET SIZE, BY PRODUCTION STAGE, 2018-2032 (USD MILLION)
  • TABLE 374. CHINA VIRAL VECTORS MARKET SIZE, BY DOWNSTREAM, 2018-2032 (USD MILLION)
  • TABLE 375. CHINA VIRAL VECTORS MARKET SIZE, BY PURIFICATION, 2018-2032 (USD MILLION)
  • TABLE 376. CHINA VIRAL VECTORS MARKET SIZE, BY UPSTREAM, 2018-2032 (USD MILLION)
  • TABLE 377. CHINA VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 378. CHINA VIRAL VECTORS MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 379. CHINA VIRAL VECTORS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 380. CHINA VIRAL VECTORS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 381. CHINA VIRAL VECTORS MARKET SIZE, BY VACCINE, 2018-2032 (USD MILLION)
  • TABLE 382. CHINA VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 383. UNITED STATES VIRAL VECTORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 384. UNITED STATES VIRAL VECTORS MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 385. UNITED STATES VIRAL VECTORS MARKET SIZE, BY ADENO ASSOCIATED VIRUS, 2018-2032 (USD MILLION)
  • TABLE 386. UNITED STATES VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 387. UNITED STATES VIRAL VECTORS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2032 (USD MILLION)